2.65 Preliminary Evidence for a Modified Modular Cbt Approach to the Treatment of Depression and Anxiety in Adolescent Inpatients

2018 ◽  
Vol 57 (10) ◽  
pp. S180
Author(s):  
Katherine V. Miller ◽  
Kathryn DeLonga ◽  
Chana Engel ◽  
Chris Gagnon ◽  
Keith Baptiste ◽  
...  
Keyword(s):  
Preliminary Evidence ◽  
Depression And Anxiety ◽  
Treatment Of Depression ◽  
Adolescent Inpatients

EMDR Therapy and Psycho-Oncology

2016 ◽  
Vol 10 (3) ◽  
pp. 135-137 ◽  
Author(s):  
Louise Maxfield
Keyword(s):  
Traumatic Stress ◽  
Preliminary Evidence ◽  
Daily Basis ◽  
Depression And Anxiety ◽  
Patients With Cancer ◽  
Difficult Time ◽  
Treatment Of Depression ◽  
New Research ◽  
Emdr Therapy

Cancer is not only a debilitating disease; it can also have devastating effects on a patient’s mental health and quality of life. Although the literature shows that mortality rates may be improved with the provision of effective treatment, most psychotherapy provided to patients with cancer tends to be quite generic and not always effective. Very few research studies have investigated the provision of trauma-focused therapies to this underserved population. Eye movement desensitization and reprocessing (EMDR) therapy has well-established efficacy in the treatment of traumatic stress and preliminary evidence in the treatment of depression and anxiety. It is a very effective and accessible treatment for patients with cancer. Because it does not require homework, it is less demanding than many other forms of treatment. It can be provided on an intensive (twice) daily basis, making it available to patients traveling from out of town for their cancer treatment. For those patients unable to manage trauma-focused treatment during a difficult time, it can be used to enhance personal resources. EMDR therapy can be administered in individual, group, and couple formats and is suitable for children as well as adults. New research provides promising results for the application of EMDR for patients with cancer.

scholarly journals Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review

Life ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1186
Author(s):  
Mateusz Kowalczyk ◽  
Edward Kowalczyk ◽  
Paweł Kwiatkowski ◽  
Łukasz Łopusiewicz ◽  
Monika Sienkiewicz ◽  
...  
Keyword(s):  
Antidepressant Effect ◽  
Depression Symptoms ◽  
Drug Resistant ◽  
Depression And Anxiety ◽  
Psychoactive Substances ◽  
Worldwide Population ◽  
Treatment Of Depression ◽  
Resistant Depression ◽  
Depressive Episodes ◽  
Rapid Treatment

The SARS-CoV-2 coronavirus epidemic has led to an increase in the number of people with depression. Symptoms related to the mental sphere (mainly depression and anxiety) may be experienced by one third of the worldwide population. This entails the need for the effective and rapid treatment of depressive episodes. An effective drug seems to be s-ketamine, which was accepted in March 2019 by the Food and Drug Administration (FDA) for the treatment of drug-resistant depression. This drug provides a quick antidepressant effect with maximum effectiveness achieved after 24 h. It also appears to reduce the occurrence of suicidal thoughts. However, research into undesirable effects, especially in groups of people susceptible to psychotic episodes or those who use alcohol or psychoactive substances, is necessary.

Gene–environment interactions in animal models of depression and anxiety

2019 ◽  
pp. 63-76
Author(s):  
Daniela Felice ◽  
Anand Gururajan ◽  
Olivia F O’Leary ◽  
John F Cryan
Keyword(s):  
Anxiety Disorders ◽  
Target Genes ◽  
Preclinical Studies ◽  
Depression And Anxiety ◽  
Complex Interactions ◽  
Gene Environment ◽  
Animal Models Of Depression ◽  
Treatment Of Depression ◽  
Candidate Target ◽  
The Individual

Depression and anxiety disorders cause the greatest global disability in terms of impact on the individual, family, and society at large. The etiology of these disorders is multifactorial and includes complex interactions between genetic and environmental risk factors. This chapter reviews preclinical studies assessing the importance of gene–environment (G×E) interaction. Specifically, we focus on G×E studies assessing the roles of the hypothalamic–pituitary–adrenal (HPA) axis, serotonergic system, GABAergic system, and brain-derived neurotrophic factor (BDNF) system. Finally, novel candidate target genes for the treatment of depression and anxiety disorders are considered.

Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery

2020 ◽  
Author(s):  
Maria Salvina Signorelli ◽  
Teresa Surace ◽  
Marcello Migliore ◽  
Eugenio Aguglia
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Mood Disorders ◽  
Psychiatric Symptoms ◽  
Depression And Anxiety ◽  
Lung Cancer Patients ◽  
Patients With Cancer ◽  
Treatment Of Depression ◽  
The Impact

Cancer is a leading cause of death worldwide. Literature reports depression and anxiety are the most common psychiatric symptoms in cancer patients. Notably, lung cancer is associated with major depressive disorder in 5–13% of cases. The present article aims to give an overview regarding the impact of mood disorders on the outcomes of patients affected by lung cancer. Our review showed that pharmacological treatment and psychotherapy can be useful to improve the quality of life of patients with lung cancer. Moreover, the treatment of depression and anxiety can be associated with a reduced mortality. In conclusion, it is important to consider psychiatric care as important as other adjuvant oncologic therapies in patients with cancer.

Sign in / Sign up

Export Citation Format

Share Document